Award details

Translational investigation of a lithium mimetic on emotional and cognitive processing in healthy volunteers

Reference	BB/J021547/1
Principal Investigator / Supervisor	Dr Grant Churchill
Co-Investigators / Co-Supervisors	Professor Philip Cowen, Professor Catherine Harmer
Institution	University of Oxford
Department	Pharmacology
Funding type	Research
Value (£)	152,136
Status	Completed
Type	Research Grant
Start date	30/07/2012
End date	30/04/2014
Duration	21 months

Abstract

unavailable

Summary

Bipolar disorder disease is a chronic illness characterized by recurrent episodes of aberrant mood that affects around 3% of the world's population. Current therapies for bipolar disorder such as lithium, valproic acid and atypical antipsychotics, such as seroquel, cause serious side effects including liver and kidney damage. There is therefore an urgent need for new therapies that allow long-term mood stabilisation in patients, but are more favourably tolerable. In this project, we propose to confirm the suitability of a known antioxidant that has proven to be safe in humans as a lithium replacement candidate. Our drug inhibits the enzyme inositol monophosphatase, a candidate therapeutic target of lithium and also alters mood and behaviour in animals in a manner similar to lithium. This drug, if successful therefore, would offer for the first time, the potential for physicians to treat bipolar patients without exposing them to harmful side effects.

Committee	Not funded via Committee
Research Topics	Neuroscience and Behaviour, Pharmaceuticals
Research Priority	X – Research Priority information not available
Research Initiative	Follow-On Fund (FOF) [2004-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search